Aktieanalys

Xbrane Biopharma: Streamlined development plan for Xdivane - Redeye

{newsItem.title}

Redeye Publicerad: 27 Sep 2024 12:49

Xbrane Biopharma

Redeye comments on Xbrane following today's news that the FDA, like the EMA, has recieved positive feedback for a streamlined development plan for Xdivane. This is expected to significantly reduce both the cost and duration of clinical development.

Länk till analysen i sin helhet: https://www.redeye.se/research/1041064/xbrane-biopharma-streamlined-development-plan-for-xdivane?utm_source=finwire&utm_medium=RSS

Nyheter om Xbrane Biopharma

Läses av andra just nu

Om aktien Xbrane Biopharma

Senaste nytt